Barclays analyst Matt Miksic raised the firm’s price target on Abbott to $125 from $122 and keeps an Overweight rating on the shares. The company reported sequential improvements in medical device growth and diabetes, exiting 2022 with strong underlying momentum, positioning it for high single digit growth in 2023, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ABT:
- Abbott approval ‘incremental headwind’ to Nevro, says Piper Sandler
- Abbott: FDA approves Proclaim XR spinal cord stimulation system
- Abbott price target raised to $125 from $110 at Stifel
- Abbott price target raised to $123 from $109 at Raymond James
- Abbott price target raised to $132 from $125 at Bernstein